A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

Inclusion Criteria: * Males and females between 12 and 55 years of age. * Meets the DSM-5 diagnostic criteria for Autism Spectrum Disorder (ASD) as established by clinical diagnostic interview * At least moderate severity of ASD impairment as measured by a raw score of ≥85 on the SRS * Participants and their parent/guardian must be able to speak and understand English sufficiently to comprehend the nature of the study and to allow for the completion of all study procedures required per protocol. * Subjects and their parent/guardian must be considered reliable reporters. They must understand the nature of the study and must sign an IRB-approved informed consent form before initiation of any study procedures. Subjects and their parent/guardian must have a level of understanding sufficient to communicate with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol. * Each subject and their parent/guardian must understand the nature of the study and provide written informed assent/consent. * Subjects with mood, anxiety, or disruptive behavior disorders will be allowed to participate in the study provided they do not meet any exclusionary criteria. * If the subject is sexually active, he/she must agree to use an acceptable form of birth control during the study. These include: * Abstinence (no sexual contact) * A barrier method (diaphragm plus spermicide or a condom plus spermicide) in addition to one of the following methods: * Consistent use of an approved birth control pill * Birth control patch * Injected contraceptives * Intrauterine device (IUD) Exclusion Criteria: * Impaired intellectual functioning and/or impaired spoken language. * Clinically unstable psychiatric conditions or any serious medical illness, which will be assessed by study clinicians during the psychiatric interview and medical history review. If the clinical assessment suggests a psychiatric or medical condition demanding acute clinical attention, then the subject will be excluded from participating in the trial. * Clinically unstable psychiatric conditions. * Any serious medical illness * Pregnant or nursing females. * Known hypersensitivity to oxytocin. * Severe allergies or multiple adverse drug reactions. * A non-responder or history of intolerance to oxytocin, after treatment at adequate doses as determined by the clinician. * Subjects with significant nasal pathology (including atrophic rhinitis, recurrent nose bleeds, and history of hypophysectomy). * Clinically abnormal baseline laboratory values falling significantly outside of the standard reference ranges for a basic metabolic screen. * Investigator and his/her immediate family defined as the investigator's spouse, parent, child, grandparent, or grandchild. * Currently enrolled or recently participated (within the past 6 months) in a clinical trial of intranasal oxytocin.